EU Rejects Cymbalta For Fibromyalgia Treatment
By Erin Marie Daly ( October 24, 2008, 12:00 AM EDT) -- In a blow to Eli Lilly & Co., the European Union's drug-regulating body has recommended against allowing the pharmaceutical giant to market Cymbalta as a fibromyalgia treatment after finding that the benefits of the drug – which is already approved in Europe for depression and anxiety – in the treatment of the disease do not outweigh its risks....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.